Year: 2024
Type: article
Abstract: A recent phase I clinical study tested anti-ROR1 chimeric antigen receptor (CAR) T cells in patients with chronic lymphocytic leukemia, non-small cell lung cancer, and triple-negative breast cancer. The product could be safely administered and had activity in chronic lymphocytic leukemia but less so in non-small cell lung cancer and triple-negative breast cancer. See related article by Jaeger-Ruckstuhl et al., p. 503.
Source: Clinical Cancer Research
Author: Sebastian Kobold
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Melanoma Research Alliance, European Commission, Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Bayerische Forschungsstiftung, Else Kröner-Fresenius-Stiftung, José Carreras Leukämie-Stiftung, Ludwig-Maximilians-Universität München, Deutsche Krebshilfe, Hector Stiftung, Hector Stiftung II, Elitenetzwerk Bayern, HORIZON EUROPE European Research Council
Awards: Define a lead candidate for clinical development of a novel T cell therapy, G1809379011, G2576477382, G2902734143, G434337789, G4963151808, G6179138625, G6209871035, Training Network for Optimizing Adoptive T cell Therapy of Cancer, Bispecific antibodies and T cell activating proteins against melanoma, G782482008, Cancer tailored next generation cellular therapies
OpenAlex ID: W4404958946